A phase 1 study of blinatumomab/lenalidomide in relapsed/refractory B-cell lymphoma: toxicity, efficacy, and correlative analysis

Abstract: Despite a recent increase in therapeutic options, patients with relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL) eventually require novel therapies. We conducted a phase 1 trial of blinatumomab and lenalidomide in R/R B-NHL. Three dose levels representing 2 schedules were explor...

Descripció completa

Dades bibliogràfiques

Autors principals:	Joseph M. Tuscano, Tamer Othman, Paul Frankel, Christopher Ruel, Christina Poh, Samantha Herbert, Emanual Maverakis, Alexander A. Merleev, Guillaume Luxardi, Mehrdad Abedi, Raghuveer Ranganathan, Dipenkumar Modi, Jasmine Zain, Elizabeth L. Budde, Matthew Mei, Aaron S. Rosenberg, Rasmus T. Hoeg, Caitlin Costello, Francine M. Foss, Basem M. William, H. Kent Holland, Elad Sharon, Howard Streicher, Alexy Danilov, Edward Newman
Format:	Artigo
Idioma:	Inglês
Publicat:	Elsevier 2026-02-01
Col·lecció:	Blood Advances
Accés en línia:	http://www.sciencedirect.com/science/article/pii/S2473952925007049
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!